Navigation Links
Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Date:9/25/2008

Data Validates Neuroprotective Effect of Quark's New RNAi Product on Dying Retinal Ganglion Cells, a Cause of Blindness in Glaucoma

FREMONT, Calif., Sept. 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced QPI-1007 as the Company's first siRNA drug candidate based on its own intellectual property for a host of novel structures having freedom to operate in the siRNA IP space. QPI-1007, which is currently being evaluated in advanced IND enabling preclinical studies as a neuroprotective agent for eye diseases, is the first drug candidate to utilize a novel siRNA structure developed by Quark free of third party IP. The Company is utilizing its proprietary structures and intellectual property to develop additional RNAi drug candidates in its robust pipeline.

Quark has completed studies with QPI-1007 in different animal models of acute and severe optic nerve injury. In collaboration with Prof. Ann Logan of the Division of Medical Sciences, Department of Medicine, University of Birmingham, UK, Quark examined QPI-1007's effectiveness in a model of retinal ganglion cell (RGC) death by optic nerve crush (ONC). In a second study of QPI-1007 in collaboration with Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Universite de Montreal, its effectiveness was examined in a model of RGC death induced by axotomy of the optic nerve. QPI-1007 displayed neuroprotective activity towards RGCs. It significantly protected retinal neurons against delayed degeneration and reduced injury induced RGC death in vivo, the hallmarks of glaucoma and acute injuries such as ischemic optic neuropathy.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "With more RNAi products in human trials than any other company in the industry, Quark has proven its ability to advance siRNA products from discovery to the clinic.
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... MEETING, Pa., Nov. 20 ...hat questions why currently available medications ...ng ignored, ECRI Institute, an independent nonprof...ence on Finasteride for Prevention of Prostate Ca...2009, New York Times article, " Drugs to Deter S...
(Date:11/19/2009)...land, Nov. 19 Warner Chilcott plc ...s previously announced secondary offering of 20,00...lic of $22.25 per share. The selling shareholders...rs, DLJ Merchant Banking, J.P. Morgan Partners (ad... L.P., certain other institutional investors and m...
(Date:11/19/2009)...N, Taiwan, Nov. 19 /PRNewswire-Asia/ -- ScinoPharm...al ingredients (APIs), announced that its,Tainan f...rtification from,SafeBridge(R) Consultants, Inc. T...and proficiency in the safe handling of potent act... to specific laboratories and,production areas use...
Breaking Medicine Technology:ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 2ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer: New Hotline Report to Aid Healthcare Decision Makers and Journalists 3Warner Chilcott Prices Secondary Equity Offering 2Warner Chilcott Prices Secondary Equity Offering 3Warner Chilcott Prices Secondary Equity Offering 4ScinoPharm Announces SafeBridge Potent Compound Safety Certification 2Timing of Oxygen After a Stroke May Matter 59768 1Timing of Oxygen After a Stroke May Matter 59768 2PSA Nanotest May Spot Prostate Cancers Return After Surgery 59766 1PSA Nanotest May Spot Prostate Cancers Return After Surgery 59766 2PSA Nanotest May Spot Prostate Cancers Return After Surgery 59766 3Mercury Levels Not Abnormal in Autistic Children 59764 1Mercury Levels Not Abnormal in Autistic Children 59764 2Mercury Levels Not Abnormal in Autistic Children 59764 3
(Date:11/20/2009)...swire-FirstCall/ - NUCRYST Pharmaceuticals Corp. a...ers will be held on Monday, December 21, 2009. The... two special resolutions. The first special resolu...r substantially all of the assets of NUCRYST, subs...urchase agreement dated November 10, 2009 among th...
(Date:11/20/2009)...wire/ -- Following a recall by Unilever The Stop &...edd,s Country Crock ® Side Dishes DELUXE Ched... Side Dishes DELUXE Four Cheese Pasta due to an un...de dates and UPCs are affected: ,, Shedd,s Cou...oli Rice 21 oz, UPC 027400218316, Best By NOV 29 0...
(Date:11/20/2009)...SNewswire/ -- The American Dental Association (ADA...n (FDA) to establish appropriate classifications f...n about the safety of whitening products that are ...onal consultation or examination by a dentist, the...ly based tooth whitening or bleaching agents can h...
(Date:11/20/2009)...PRNewswire-USNewswire/ -- Samuel Gladding is no Sc...means to be "happy" during the holidays. As a lice...mily counseling and chair of the Department of Cou...esearch shows that it is the pressure to be happy ...ring the holidays. ,, That,s why he,s challengi...
(Date:11/20/2009)...20 in the Journal of the National Cancer Institut...often appear in news coverage of cancer research. ... and journals to help alleviate the problem. , L...M.D., M.S., of Center for Medicine and the Media a...inical Practice in New Hampshire, and Barnett S. K...
Breaking Medicine News(10 mins):Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2Health News:Why Holidays Don't Have To Be 'Happy' 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2
...h Nassau Communities Hospital here has appointed a...s surgery department.// Rajiv Datta is recognised ...s an internationally known leader in surgical onco... said. Datta also serves as the hospital's ...
...om many adults developing symptoms of diabetes and... of teenagers prone to cardiac problems. //A longi... beverages saturated with sugar during early stage... and type-2 diabetes has largely dealt with adults...
...sted Reproduction Unit at Quiron Hospital have suc...n a woman who is a carrier// of the disease Retino... order to avoid giving birth to a male child. This...itary illness of the eyes of a degenerative nature...
...dard treatment for new born babies who develop jau...strong light.// French researchers say that this i... skin of the babies later in life. Such moles are ... that it is important to ensure that new borns are...
...s (skin cancers) are more likely to grow rapidly i...gular borders or have symptoms//, according to a r...s more likely to occur in elderly men and individu...otal experience suggests that there is a form of r...
...study involving 44,000 American men aged 65 to 80 ...urgery// or radiation had about 30 % more chances ...ccording to the American Cancer Society estimate, ...has been that observation or 'watchful waiting' wa...
Other Medicine News:Health News:Cardiac Risk is Reduced by Cutting the Sugar in Your Drink 2Health News:Cardiac Risk is Reduced by Cutting the Sugar in Your Drink 3Health News:Characteristics of Fast-Growing Skin Cancers 2Health News:Survival Rate Better In Men Treated For Prostate Cancer Than Who Opt For ‘Wait And Watch’ Approa 2
XE-2100
Coulter LH 750 Hematology Analyzer
...he CKX microscopes utilize the infinity-corrected ...lity in cell checking. Olympus has taken this one ...esign approach with the capability of a fluorescen...th digital imaging and video monitoring. The CKX41...
CX41 Microscopes
Medicine Products: